International Journal of Pharma Research & <strong>Review</strong>, June 2013; 2(6):36-44 ISSN: 2278-6074Aliasgar Shahiwal, Shrenik P. Shah, Received16 June 2003, Revised 26 June 2003.5. K. A. Witt, T. J. Gillespie, J. D. Huber, R. D.Egleton, T. P. Davis, Peptides 2001, 22,2329.6. M. S. Alavijeh, M. Chishty, M. Z. Qaiser, A. M.Palmer, NeuroRx 2005, 2, 554.7. R. D. Egleton, T. P. Davis, Peptides 1997, 18,1431.8. J. F. Deeken, W. Loscher, Clin. Cancer Res.2007, 13, 1663.9. W. M. Pardridge, Pharm. Sci. Technol. Today1999, 2, 49.10. A. G. de Boer, P. J. Gaillard, Clin.Pharmacokinet. 2007, 46, 553.11. H. Kusuhara, Y. Sugiyama, <strong>Drug</strong> DiscoveryToday 2001, 6, 150.12. Siegal, T. and zylber-Katz, E., Strategies <strong>for</strong>increasing drug delivery to the brain: focuson brain lymphoma, ClinPharmacokinet, 41:171-186, 2002.13. Arun Rasheed, I Theja, et al., CNSTARGETED DRUG DELIVERY: CURRENTPERSPECTIVES, JITPS 2010, Vol. 1 (1), 9-18.14. Bellavance MA, Blanchette M, Fortin D.Recent advances in blood–brain barrierdisruption CNS delivery strategy. AAPS. J.10(1), 166–177 (2008).15. Gabathuler R. <strong>Approaches</strong> to transporttherapeutic drugs across the blood–brainbarrier to treat brain diseases. Neurobiol.Dis. 37(1), 48–57 (2010).16. Jones AR, Shusta EV. Blood–brain barriertransport of therapeutics via receptormediation.Pharm. Res. 24(9), 1759–1771(2007).17. Pardridge WM. <strong>Brain</strong> drug development andbrain drug targeting. Pharm. Res. 24(9),1729–1732 (2007).18. Pardridge WM. <strong>Drug</strong> targeting to the brain.Pharm. Res. 24(9), 1733–1744 (2007).19. Rip J, Schenk GJ, de Boer AG. Differentialreceptor-mediated drug targeting to thediseased brain. Expert Opin. <strong>Drug</strong> Deliv. 6(3),227–237 (2009).20. Bickel U, Yoshikawa T, Pardridge WM.<strong>Delivery</strong> of peptides and proteins throughthe blood–brain barrier. Adv. <strong>Drug</strong> Deliv.Rev. 46(1–3), 247–279 (2001).21. Lu W, Wan J, She Z, Jiang X. <strong>Brain</strong> deliveryproperty and accelerated blood clearance ofcationic albumin conjugated pegylatednanoparticle. J. Control. Release 118(1), 38–53 (2007).22. Reddy JS, Venkateswarlu V. <strong>Novel</strong> deliverysystems <strong>for</strong> drug targeting to the brain.<strong>Drug</strong>s Future 2004; 29: 63-69.23. Kabanov AV, Batrakova EV. Newtechnologies <strong>for</strong> drug delivery across theblood brain barrier. Curr Pharm Des 2004;10: 1355-1363.24. Mishra A, Ganesh S, Shahiwala A, Shah SP.<strong>Drug</strong> delivery to the central nervous system:a review. J Pharm Pharm Sci 2003; 6(2):252-273.25. Moghimi, S.M.; Hunter, A.C.; Murray, J.C.Long-circulating and target-specificnanoparticles: theory to practice.Pharmacol. Rev. 2001, 53, 283-318.26. Ogawara, K.; Furumoto, K.; Takakura, Y.;Hashida, M.; Higaki, K.; Kimura, T. Surfacehydrophobicity of particles is notnecessarily the most important determinantin their in vivo disposition after intravenousadministration in rats. J. Control. Release2001, 77, 191-198.27. Huwyler J, Wu D, Pardridge WM. <strong>Brain</strong> drugdelivery of small molecules usingimmunoliposomes. Proc Natl Acad Sci USA1996; 93: 14164-14169.28. Pardrige, W.M., Huwyler, J.: WO022092A1(1998).29. Tosi, G.; Costantino, L.; Ruozi, B.; Forni, F.;Randelli, M.A. Polymeric nanoparticles <strong>for</strong>the drug delivery to the central nervoussystem. Exp. Opin. <strong>Drug</strong> Deliv. 2008, 5 (2),155-174.30. Yang, S.; Zhu, J.; Lu, Y.; Liang, B.; Yang, C.Body distribution of camptothecin solidlipid nanoparticles after oral administration.Pharm. Res. 1999, 16, 751-757.31. Zara, G.P.; Cavalli, R.; Bargoni, A.; Fundaro,A.; Vighetto, D.; Gasco, M.R. Intravenousadministration to rabbits of non-stealth andstealth doxorubicin-loaded solid lipidnanoparticles at increasing concentrationsof stealth agent: pharmacokinetics anddistribution of doxorubicin in brain andother tissues. J. <strong>Drug</strong> Target. 2002, 10, 327-335.32. Wong, H. L.; Bendayan, R.; Rauth, A. M.; Li,Y.; Wu, X.Y. Chemotherapy with anticancerdrugs encapsulated in solid lipidnanoparticles. Adv. <strong>Drug</strong> Deliv. Rev. 2007, 59,491-50433. Chattopadhyay, N.; Zastre, J.; Wong, H.L.;Wu, X.Y.; Bendayan, R. Solid lipidnanoparticles enhance the delivery of theHIV protease inhibitor, atazanavir, by ahuman brain endothelial cell line. Pharm.Res. 2008, 25, 2262-71.34. Adams ML, Lavasanifar A, Kwon GS.Amphiphilic block copolymers <strong>for</strong> drugdelivery. J Pharm Sci 2003; 92: 1343-1355.35. Jones M, Leroux J. Polymeric micelles-a newgeneration of colloidal drug carriers. Eur JPharm Biopharm 1999; 48: 101-111.Swatantra Bahadur Singh, IJPRR 2013; 2(6) 43
International Journal of Pharma Research & <strong>Review</strong>, June 2013; 2(6):36-44 ISSN: 2278-607436. Allen C, Maysinger D, Eisenberg A. Nanoengineeringblock copolymer aggregates <strong>for</strong>drug delivery. Colloids Surf B Biointerfaces1999; 16: 3-27.37. Kabanov AV, Batrakova EV, Melik-NubarovNS, et al. New classes of drug carries:micelles of poly(oxyethylene) -poly(oxypropylene block copolymersasmicrocontainers <strong>for</strong> drug targeting <strong>for</strong>mblood in brain. J Control Release 1992; 22:141-158.38. Huwyler J, Wu D, Pardridge WM. <strong>Brain</strong> drugdelivery of smallmolecules usingimmunoliposomes. Proc Natl Acad Sci USA1996; 93: 14164-14169.39. C. Rousselle, P. Clair, J. M. Lefauconnier, M.Kaczorek, J. M. Scherrmann, J. Temsamani,Mol. Pharmacol. 2000, 57, 679.Swatantra Bahadur Singh, IJPRR 2013; 2(6) 44
Change language